Sarcoma: when insurers say no, reviewers often say yes

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for a BostonGene tumor portrait comprehensive genomic profiling test. Morphologic diagnosis based on microscopic examination of histologic sections remains the gold standard for the treatment of patients with a diagnosis of sarcoma. Several techniques are useful in support of morphologic diagnosis including immunohistochemical (IHC) staining, cytogenetics, electron microscopy, and molecular genetic testing. Since many sarcoma types harbor characteristic genetic aberrations, molecular genetic testing has emerged as a helpful testing approach to identify single base pair substitutions, deletions, amplifications, and translocations.

Findings: The physician reviewer found that The patient has requested authorization and coverage for proton beam therapy. Proton beam has unique properties compared to standard photon or x-ray beam in its ability to deposit radiation doses. The use of proton beams potentially results in fewer areas of low scattered radiation dose as fewer proton beams may be used to achieve a dose distribution similar to standard photon beams, potentially resulting in less radiation exposure to critical organs. The use of proton beams in treating the chest wall and mediastinum is well-studied. The National Comprehensive Cancer Network (NCCN) guidelines support the use of proton beams in the chest region when a reduction in dose to organs at risk is required that cannot be achieved by other radiation techniques.

Where the denial was upheld

Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for stereotactic body radiation therapy (SBRT).Radiation treatment in both the pre-operative and post-operative setting has played a significant role in the treatment of soft tissue sarcomas of the extremities. Per the National Comprehensive Cancer Network (NCCN guidelines), there is a benefit to pre-operative radiation treatment of extremity sarcomas as compared to post-operative treatment. SBRT delivers high doses of radiation treatment in fewer sessions. It has found a significant role in certain disease sites, such as brain metastases and early-stage lung cancers. However, the role of SBRT in the setting of soft tissue sarcoma of the extremity is still an active area of research.

Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for proton beam therapy delivered as 30 Gy in 5 fractions.Proton therapy is not considered more beneficial than standard treatment with photons for soft tissue metastases. When treating metastases, the primary objective is to alleviate pain, stabilize the affected bones, and enhance the patient's overall quality of life. Standard photon radiation, delivered through modern techniques like intensity-modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT), can precisely target the metastatic lesions while sparing surrounding healthy tissues. This ensures effective pain relief and tumor control, making it a medically sufficient option for the patient.

These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for sarcoma was denied, the published record says the denial is worth fighting.